The decision by Express Scripts to make the AbbVie hepatitis C treatment the exclusive option for patients with the most common type of the virus caused a ruckus on Wall Street, although the reaction among some doctors and patient advocates was mixed. For Gilead Sciences, the market leader in hepatitis C drugs, the move by the big pharmacy benefits manager was the proverbial bitter pill. Gilead shares plunged 14% to $92.90, wiping out more than $20 billion in market capitalization over expectations of a big hit to sales.. Ballparking the hepatitis C market, however, can be tricky, given the different forms of the disease, the recommended durations for the competing treatments and, most of all, the willingness of physicians to prescribe one drug instead of another. So we spoke to doctors, patient advocates and other drug-benefit providers to get their takes. And here’s what we found…